Shorter antibiotic treatment for heart device infections
Part of Infections clinical trials.
This trial tests whether a shorter course of antibiotics is as safe and effective as the standard longer course for people who have had an infected heart device removed. It aims to reduce side effects and make treatment easier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed infection of your heart device (pacemaker or defibrillator) that required removal of the device.
- You have had the infected device completely removed.
- You are covered by French National Health Insurance.
- You agree to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares removing a heart device (like a pacemaker) versus using antibiotics and other medical care to treat an infection. It may help doctors decide the best way to handle infections related to these devices.
This trial tests if a new, faster approach to replacing an infected pacemaker or defibrillator is safe. If you have a heart device infection and meet recovery milestones, you might be able to get a new device sooner than usual.
This trial studies whether people with an implanted heart device infection should take antibiotics for life or stop antibiotics and monitor closely. It is for situations where doctors think removing the device is not a safe or suitable option.
This study tests a new antibiotic called oritavancin for treating skin infections at the site of heart devices like pacemakers or defibrillators, especially when caused by drug-resistant bacteria. The goal is to see if this once-daily antibiotic works as well as the standard treatment.
This trial compares taking antibiotics by mouth versus receiving antibiotics through a vein (outpatient IV) for an infection of the heart valve. It’s designed to see whether the oral option can work as well and safely, especially after initial treatment and surgery if needed.
This trial tests whether a treatment without rifampin works as well as one with rifampin for a type of heart valve infection caused by staph bacteria. It aims to find a simpler and safer option for patients with an infected artificial heart valve.
Hear when a new Cardiac Devices Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.